II.1)
Scope of the procurement
Aseptically Manipulated or Terminally Sterile Medicinal Products
Reference number:
T22/0446
33600000
-
Pharmaceutical products
Supplies
II.1.4)
Short description
The supply of aseptically manipulated or terminally sterile products to NHS Trusts within the boundaries of the Peninsula Purchasing and Supply Alliance (PPSA). Products include national dose-banded cytotoxic and non-cytotoxic batch and patient specific medicines in ready-to-use infusion bags and pre-filled syringes.
This procurement is being managed by the Peninsula Purchasing and Supply Alliance (hereafter referred to as the PPSA) on behalf of the Royal Devon University Healthcare NHS Foundation Trust (hereafter referred to as the Organisation) acting for itself and for Gloucestershire Hospitals NHS Trust, Great Western Hospitals NHS Foundation Trust, Royal Cornwall Hospitals NHS Trust, Salisbury NHS Foundation Trust, Somerset NHS Foundation Trust, Torbay & South Devon NHS Foundation Trust, University Hospitals Plymouth NHS Trust, North Bristol NHS Trust, University Hospitals Bristol & Weston NHS Foundation Trust and the Royal United Hospital Bath NHS Foundation Trust.
II.1.5)
Estimated total value
Value excluding VAT: 80500000.00
GBP
II.1.6)
Information about lots
This contract is divided into lots:
yes
Tenders may be submitted for
all lots
Aseptically prepared products
Lot No:
1
II.2.2)
Additional CPV code(s)
33690000
-
Various medicinal products
33692100
-
Infusion solutions
33692500
-
Injectable solutions
33692510
-
Intravenous fluids
33693100
-
Toxins
II.2.3)
Place of performance
NUTS code:
UKK -
SOUTH WEST (ENGLAND)
NUTS code:
UK -
UNITED KINGDOM
Main site or place of performance:
Bristol, Devon, Cornwall, Gloucestershire, Somerset & Wiltshire
II.2.4)
Description of the procurement
Supply of Cyclophosphamide, Doxorubicin & Pembrolizumab compounded ready-to-use batch and patient-specific products.
Price is not the only award criterion and all criteria are stated only in the procurement documents
Value excluding VAT: 46000000.00
GBP
II.2.7)
Duration of the contract, framework agreement or dynamic purchasing system
Duration in months:
48
This contract is subject to renewal:
no
II.2.10)
Information about variants
Variants will be accepted:
no
II.2.11)
Information about options
Options:
yes
Description of options:
Lot 1 has the option to be extended for any period up to 36 months.
II.2.13)
Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
no
II.2.14)
Additional information
The invitation to tender (ITT) documents and additional information is available from CTM e-procurement portal at https://uk.eu-supply.com
Tenders or requests to participate must be submitted electronically via the CTM e-procurement portal at https://uk.eu-supply.com
If not already registered on CTM eu-supply.com you will need to register as a supplier to express interest.
Aseptically prepared products
Lot No:
2
II.2.2)
Additional CPV code(s)
33690000
-
Various medicinal products
33692100
-
Infusion solutions
33692500
-
Injectable solutions
33692510
-
Intravenous fluids
33693100
-
Toxins
II.2.3)
Place of performance
NUTS code:
UKK -
SOUTH WEST (ENGLAND)
Main site or place of performance:
Bristol, Devon, Cornwall, Gloucestershire, Somerset & Wiltshire
II.2.4)
Description of the procurement
Supply of Carboplatin, Epirubicin, Nivolumab & Paclitaxel.
Price is not the only award criterion and all criteria are stated only in the procurement documents
Value excluding VAT: 25000000.00
GBP
II.2.7)
Duration of the contract, framework agreement or dynamic purchasing system
Duration in months:
48
This contract is subject to renewal:
no
II.2.10)
Information about variants
Variants will be accepted:
no
II.2.11)
Information about options
Options:
yes
Description of options:
The Contract for Lot 2 has the option to be extended for any period up to 36 months.
II.2.13)
Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
no
Aseptically Prepared Products
Lot No:
3
II.2.2)
Additional CPV code(s)
33690000
-
Various medicinal products
33692100
-
Infusion solutions
33692500
-
Injectable solutions
33692510
-
Intravenous fluids
33693100
-
Toxins
II.2.3)
Place of performance
NUTS code:
UKK -
SOUTH WEST (ENGLAND)
Main site or place of performance:
Bristol, Devon, Cornwall, Gloucestershire, Somerset & Wiltshire
II.2.4)
Description of the procurement
Supply of Atezolizumab (Tecentriq®), Bortezomib Subcut, Docetaxel, Fluorouracil, Oxaliplatin & Vincristine.
Price is not the only award criterion and all criteria are stated only in the procurement documents
Value excluding VAT: 9000000.00
GBP
II.2.7)
Duration of the contract, framework agreement or dynamic purchasing system
Duration in months:
48
This contract is subject to renewal:
no
II.2.10)
Information about variants
Variants will be accepted:
no
II.2.11)
Information about options
Options:
yes
Description of options:
Lot 3 has the option to be extended for any period up to 36 months.
II.2.13)
Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
no
Aseptically Prepared Products
Lot No:
4
II.2.2)
Additional CPV code(s)
33690000
-
Various medicinal products
33692100
-
Infusion solutions
33692500
-
Injectable solutions
33692510
-
Intravenous fluids
33693100
-
Toxins
II.2.3)
Place of performance
NUTS code:
UKK -
SOUTH WEST (ENGLAND)
Main site or place of performance:
Bristol, Devon, Cornwall, Gloucestershire, Somerset & Wiltshire
II.2.4)
Description of the procurement
Supply of Bleomycin, Cabazitaxel, Calcium folinate, Cisplatin, Cytarabine, Daunorubicin, Ganciclovir, Suxamethonium & Vinblastine.
Price is not the only award criterion and all criteria are stated only in the procurement documents
Value excluding VAT: 1500000.00
GBP
II.2.7)
Duration of the contract, framework agreement or dynamic purchasing system
Duration in months:
48
This contract is subject to renewal:
no
II.2.10)
Information about variants
Variants will be accepted:
no
II.2.11)
Information about options
Options:
yes
Description of options:
Lot 4 has the option to be extended for any period up to 36 months.
II.2.13)
Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
no